靶向癌症治疗的眼科并发症以及近期发现的传统化疗的眼科并发症。
Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
作者信息
Kheir Wajiha J, Sniegowski Matthew C, El-Sawy Tarek, Li Alexa, Esmaeli Bita
机构信息
Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; American University of Beirut Medical Center, Beirut, Lebanon.
Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Surv Ophthalmol. 2014 Sep-Oct;59(5):493-502. doi: 10.1016/j.survophthal.2014.02.004. Epub 2014 Feb 18.
As our understanding of cancer pathophysiology has increased, so have the number of targeted therapeutic agents available. By targeting specific molecules involved in tumorigenesis, targeted therapeutic agents offer the potential for significant efficacy against tumor cells while minimizing the adverse effects. We highlight the recently recognized ophthalmic complications of targeted cancer therapy, as well as recently recognized complications of traditional chemotherapeutic agents.
随着我们对癌症病理生理学的理解不断加深，可用的靶向治疗药物数量也在增加。通过靶向参与肿瘤发生的特定分子，靶向治疗药物有望在最大限度减少不良反应的同时，对肿瘤细胞产生显著疗效。我们重点介绍了靶向癌症治疗最近才被认识到的眼部并发症，以及传统化疗药物最近才被认识到的并发症。
Zotero 插件